Text Size


Clinicians have long been aware of poor patient adherence to glaucoma topical drug therapy, as well as with difficulties in delivering drugs to the retina for AMD disease. Patient noncompliance results in $290 billion of direct and indirect medical costs each year.
(Source: Aug 2009, New England Healthcare Institute)

The Multibillion Dollar Opportunity

Drug delivery to the eye is a rapidly growing, multibillion dollar market opportunity with sales for diabetic macular edema (DME), age-related macular degeneration (AMD), and glaucoma drugs already surpassing $600 million, $2 billion and $4 billion respectively. Today, more than 100,000 Americans are diagnosed with wet AMD every year and glaucoma is the leading cause of preventable blindness in the United States.